Brain endothelial cell expression of SPARCL-1 is specific to chronic multiple sclerosis lesions and is regulated by inflammatory mediators in vitro

摘要: Aims Cell matrix modulating protein SPARCL-1 is highly expressed by astrocytes during CNS development and following acute damage. Applying NanoLC-MS/MS to CSF of RRMS SPMS patients, we identified as differentially between these two stages MS, suggesting a potential biomarker differentiate from role in MS pathogenesis. Methods This study examines the discriminating 3 independent cohorts (n=249), analyses its expression pattern lesions (n= 26), studies regulation cultured human brain microvasculature endothelial cells (BEC) after exposure MS-relevant inflammatory mediators. Results SPARCL-1 was significantly higher compared Dutch cohort 76 patients. This finding not replicated 2 additional patients Sweden (n=81) Switzerland (n=92). In chronic lesions, but active or NAWM, vessel observed addition astrocytes. EC were found express regulated mediators BEC. Conclusions Conflicting results SPARCL-1's differential precludes use for disease progression. The BEC together with vitro suggest neuropathology, possibly at vascular level. This article protected copyright. All rights reserved.